Gradalis Appoints Eric Hall as Chief Financial Officer
December 14, 2022 08:00 ET
|
Gradalis, Inc.
DALLAS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Gradalis, a privately-held, late-stage stage biotechnology company developing immunotherapies for ovarian and other cancers, today announced the appointment...
Gradalis to Present at the 2022 Cell & Gene Meeting on the Mesa
October 04, 2022 08:00 ET
|
Gradalis, Inc.
DALLAS, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil®, today announced that...
Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors
October 03, 2022 08:00 ET
|
Gradalis, Inc.
- In both studies, Gradalis’ lead program, Vigil, demonstrated a favorable safety profile when used in combination with checkpoint inhibitors, durvalumab or atezolizumab, without evidence of...
Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®
September 28, 2022 08:00 ET
|
Gradalis, Inc.
-Webinar to feature presentations from Rodney Rocconi, M.D. and John Nemunaitis, M.D., on Monday, October 3rd at 1:00 p.m. ET DALLAS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Gradalis, a privately-held,...
Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®
August 29, 2022 08:05 ET
|
Gradalis, Inc.
Analysis identified high expression of ENTPD1 gene in patients at baseline as a significant predictor of overall and recurrence-free survival following Vigil treatment, relative to placebo This...
Gradalis Appoints Steven Engle as Chief Executive Officer
June 02, 2022 08:58 ET
|
Gradalis, Inc.
DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, announced today that Steven Engle has joined...
Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer
March 26, 2021 11:41 ET
|
Gradalis, Inc.
Results from pre-planned subgroup analysis of stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) profile and homologous recombination proficiency (HRP) have been...
Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology
January 07, 2021 07:00 ET
|
Gradalis, Inc.
The VITAL study, published in The Lancet Oncology, demonstrates that Vigil first-line maintenance treatment resulted in improved RFS in BRCA1/2-wt ovarian cancer when compared to placebo.Importantly...
Gradalis Announces Medical Leadership Team Promotion
March 04, 2019 13:14 ET
|
Gradalis, Inc.
DALLAS, March 04, 2019 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications,...
Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group
November 09, 2018 10:04 ET
|
Gradalis, Inc.
DALLAS, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications,...